Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthracycline-taxane versus anthracycline-taxane plus carboplatin as (neo)adjuvant therapy in triple-negative breast cancer
KCT0003529Phase 3
Key facts
- Status
- Active, not recruiting
- Start
- Dec 2015
- Countries
- 1
- Sponsor
- GC Biopharma
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Drugs
- carboplatin
- Conditions
- triple-negative breast cancer (TNBC)
01
Overview
Phase 3, randomised, open-label trial of carboplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by GC Biopharma. Started Dec 2015; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Anthracycline followed by taxane
Standard (neo)adjuvant chemotherapy regimen with anthracycline followed by taxane for triple-negative breast cancer.
Anthracycline followed by taxane plus carboplatin
Experimental (neo)adjuvant regimen adding carboplatin to the anthracycline-taxane backbone for triple-negative breast cancer.
03
Who it enrols
Adult patients with triple-negative breast cancer receiving (neo)adjuvant chemotherapy; healthy volunteers are not included.
Beyond the preview
Go deeper on KCT0003529.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003529.